Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

83 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
High-dose alkylating chemotherapy in BRCA-altered triple-negative breast cancer: the randomized phase III NeoTN trial.
Vliek S, Hilbers FS, van Werkhoven E, Mandjes I, Kessels R, Kleiterp S, Lips EH, Mulder L, Kayembe MT, Loo CE, Russell NS, Vrancken Peeters MTFD, Holtkamp MJ, Schot M, Baars JW, Honkoop AH, Vulink AJE, Imholz ALT, Vrijaldenhoven S, van den Berkmortel FWPJ, Meerum Terwogt JM, Schrama JG, Kuijer P, Kroep JR, van der Padt-Pruijsten A, Wesseling J, Sonke GS, Gilhuijs KGA, Jager A, Nederlof P, Linn SC. Vliek S, et al. Among authors: vrancken peeters mtfd. NPJ Breast Cancer. 2023 Sep 9;9(1):75. doi: 10.1038/s41523-023-00580-9. NPJ Breast Cancer. 2023. PMID: 37689749 Free PMC article.
Diffuse reflectance spectroscopy for accurate margin assessment in breast-conserving surgeries: importance of an optimal number of fibers.
Veluponnar D, Dashtbozorg B, Jong LS, Geldof F, Da Silva Guimaraes M, Vrancken Peeters MTFD, van Duijnhoven F, Sterenborg HJCM, Ruers TJM, de Boer LL. Veluponnar D, et al. Among authors: vrancken peeters mtfd. Biomed Opt Express. 2023 Jul 10;14(8):4017-4036. doi: 10.1364/BOE.493179. eCollection 2023 Aug 1. Biomed Opt Express. 2023. PMID: 37799696 Free PMC article.
Changes in breast cancer treatment during the COVID-19 pandemic: a Dutch population-based study.
Eijkelboom AH, de Munck L, Menke-van der Houven van Oordt CW, Broeders MJM, van den Bongard DHJG, Strobbe LJA, Mureau MAM, Lobbes MBI, Westenend PJ, Koppert LB, Jager A, Siemerink EJM, Wesseling J, Verkooijen HM, Vrancken Peeters MTFD, Smidt ML, Tjan-Heijnen VCG, Siesling S; NABON-COVID-19 Consortium; COVID and Cancer Care-NL Consortium. Eijkelboom AH, et al. Among authors: vrancken peeters mtfd. Breast Cancer Res Treat. 2023 Jan;197(1):161-175. doi: 10.1007/s10549-022-06732-y. Epub 2022 Nov 5. Breast Cancer Res Treat. 2023. PMID: 36334188 Free PMC article.
Clinical impact of MRI-detected additional lesions in breast cancer patients with neoadjuvant systemic therapy at the Netherlands cancer institute.
van Loevezijn AA, Winter-Warnars HAO, Hernández GS, de Bloeme CM, van Duijnhoven FH, Vrancken Peeters MTFD. van Loevezijn AA, et al. Among authors: vrancken peeters mtfd. Breast Cancer Res Treat. 2023 Feb;198(1):131-141. doi: 10.1007/s10549-022-06840-9. Epub 2023 Jan 2. Breast Cancer Res Treat. 2023. PMID: 36592232
Immediate or delayed oncoplastic surgery after breast conserving surgery at the Netherlands Cancer Institute: a cohort study of 251 cases.
van Loevezijn AA, Geluk CS, van den Berg MJ, van Werkhoven ED, Vrancken Peeters MTFD, van Duijnhoven FH, Hoornweg MJ. van Loevezijn AA, et al. Among authors: vrancken peeters mtfd. Breast Cancer Res Treat. 2023 Apr;198(2):295-307. doi: 10.1007/s10549-022-06841-8. Epub 2023 Jan 24. Breast Cancer Res Treat. 2023. PMID: 36690822
De-ESCAlating RadioTherapy in breast cancer patients with pathologic complete response to neoadjuvant systemic therapy: DESCARTES study.
van Hemert AKE, van Olmen JP, Boersma LJ, Maduro JH, Russell NS, Tol J, Engelhardt EG, Rutgers EJT, Vrancken Peeters MTFD, van Duijnhoven FH. van Hemert AKE, et al. Among authors: vrancken peeters mtfd. Breast Cancer Res Treat. 2023 May;199(1):81-89. doi: 10.1007/s10549-023-06899-y. Epub 2023 Mar 9. Breast Cancer Res Treat. 2023. PMID: 36892723
[No title available]
[No authors listed] [No authors listed] PMID: 37160807
MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II-III HER2-positive breast cancer (TRAIN-3): a multicentre, single-arm, phase 2 study.
van der Voort A, Louis FM, van Ramshorst MS, Kessels R, Mandjes IA, Kemper I, Agterof MJ, van der Steeg WA, Heijns JB, van Bekkum ML, Siemerink EJ, Kuijer PM, Scholten A, Wesseling J, Vrancken Peeters MTFD, Mann RM, Sonke GS; Dutch Breast Cancer Research Group. van der Voort A, et al. Among authors: vrancken peeters mtfd. Lancet Oncol. 2024 May;25(5):603-613. doi: 10.1016/S1470-2045(24)00104-9. Epub 2024 Apr 5. Lancet Oncol. 2024. PMID: 38588682 Clinical Trial.
Radiological, pathological and surgical outcomes after neoadjuvant endocrine treatment in patients with ER-positive/HER2-negative breast cancer with a clinical high risk and a low-risk 70-gene signature.
van Olmen JP, Jacobs CF, Bartels SAL, Loo CE, Sanders J, Vrancken Peeters MTFD, Drukker CA, van Duijnhoven FH, Kok M. van Olmen JP, et al. Among authors: vrancken peeters mtfd. Breast. 2024 Jun;75:103726. doi: 10.1016/j.breast.2024.103726. Epub 2024 Apr 5. Breast. 2024. PMID: 38599047 Free PMC article.
83 results